Logan Capital's Portfolio Adjustments
Logan Capital Management Boosts Stakes in Lloyds, Novartis, and Other Major Companies
Key Points
In Lloyds Banking Group, Logan Capital Management bought an additional 112,845 shares in the 4th quarter to bring its total to 1,258,776 shares, worth $6,672,000; the article also notes that institutional investors and hedge funds own 2.15% of Lloyds’ stock.
In AppLovin, Logan increased its position to 82,358 shares (adding 1,186 shares), and the article says AppLovin makes up 2.3% of Logan’s portfolio and is its 8th-largest holding; it also reports institutional and hedge-fund ownership at 41.85%.
For Novartis, Logan’s disclosure showed it owned 58,363 shares after adding 6,058 shares in the 4th quarter, with holdings valued at $8,047,000; the article further provides company-level context including a beta of 0.46 and a market capitalization of $293.77 billion.
In Old Dominion Freight Line, Logan held 90,509 shares after purchasing 2,312 more in the 4th quarter, worth $14,192,000; the article also highlights additional activity beyond Vanguard and JPMorgan, including that Norges Bank bought a new ODFL position during the 4th quarter valued at $444,983,000 (and reports 77.82% institutional/hedge-fund ownership).
Logan Capital Management boosted its stake in Lloyds Banking Group by 9.8% in the fourth quarter, buying 112,845 additional shares to bring its total to 1,258,776 shares worth $6.67 million, according to Watchlist News. The Philadelphia-based investment firm also added to positions in AppLovin, Novartis, and Old Dominion Freight Line during the same period.
The moves reflect what analysts describe as a "barbell" strategy — pairing steady value plays like Lloyds with high-growth bets like AppLovin, which now makes up 2.3% of Logan's roughly $2.3 billion portfolio.
Lloyds Stake Grows as UK Bank Pushes Buybacks
Logan's Lloyds position is now valued at $6.67 million after the Q4 purchase. The firm is not alone. Royal Bank of Canada and AQR Capital Management also added to Lloyds positions in the same period, according to Watchlist News. Institutional investors and hedge funds together own just 2.15% of Lloyds' NYSE-listed ADR shares.
Lloyds itself has been actively returning cash to shareholders. The bank repurchased 5,000,000 shares for cancellation on June 11 as part of its ongoing buyback program. CEO Charlie Nunn has also received a grant of 6.6 million shares, signaling management confidence in the bank's direction.
AppLovin Leads Logan's Portfolio at $55.5 Million
AppLovin is Logan's 8th-largest holding and its biggest dollar position among the stocks disclosed. Logan added 1,186 shares in Q4 to reach 82,358 shares worth $55.49 million, per Watchlist News. Institutional and hedge fund ownership across the stock sits at 41.85%.
The stock has drawn sharply divided views on Wall Street. Analysts at Benchmark and Citigroup hold "Buy" ratings with price targets as high as $710, citing AppLovin's AI-driven "Axon" advertising platform. The company reported 59% revenue growth and an 85% adjusted EBITDA margin in Q1 2026. Some analysts, however, flag insider selling as a sign the stock may be nearing a short-term peak.
Norges Bank's $445 Million ODFL Bet Towers Over Logan's Buy
Logan added 2,312 shares of Old Dominion Freight Line in Q4, bringing its total to 90,509 shares worth $14.19 million. But the headline move in the stock came from Norway's sovereign wealth fund. Norges Bank took a brand-new position in ODFL valued at $444.98 million during the same quarter, according to Watchlist News.
Vanguard and JPMorgan also increased their ODFL exposure in Q4. Institutional and hedge fund ownership in the freight carrier now stands at 77.82%. One cautionary note: Chairman David Congdon sold 52,000 shares worth roughly $10.1 million in February 2026, a move some analysts flagged as a potential signal.
Novartis Stake Grows as Pharma Giant Sheds Generic Divisions
Logan added 6,058 Novartis shares in Q4, a 11.6% increase, bringing its total to 58,363 shares worth $8.05 million, per Watchlist News. Novartis carries a market cap of $293.77 billion and a beta of just 0.46 — meaning its stock moves far less than the broader market. Institutional ownership sits at 13.12%.
The Swiss drugmaker has been reshaping itself into a "pure-play" innovative medicines company. In February 2026, it sold its 70.68% stake in its Indian generics unit to ChrysCapital for $159 million. The strategy mirrors a broader trend in Big Pharma to spin off slower-growth divisions and focus on high-margin drug development.
Sentiment
Mostly PositivePublishers
26
Articles
9
Reach
35
